Qiming Venture Partners Weekly | Top 10 Portfolio Company Updates Vol.19, June 9, 2026

Editor's Note: In 2026, the Qiming Weekly gets a refresh — updated regularly every week with just ten handpicked highlights from Qiming Venture Partners' portfolio companies, covering funding milestones and breakthrough developments.

Every step entrepreneurs take in the waves of technology and innovation deserves to be recorded. Qiming Venture Partners will continue accelerating and empowering founders, and we invite you to follow these milestone moments alongside us.

Funding News

01/

Yuanli Lingji Completes Mega-Merger and New Funding Round

Recently, Qiming Venture Partners portfolio company Yuanli Lingji completed a merger with fellow Qiming portfolio company Atomix, a logistics robotics firm, through an equity acquisition, and closed a new strategic funding round. In the second half of embodied intelligence, models and scenarios must be deeply integrated. This merger marks the first time in China's embodied intelligence track that models and scenarios have truly grown together.

"Models and scenarios have never existed in isolation. This merger achieves a 'two-way embrace' between models and scenarios," said Tang Wenbin, founder and CEO of Yuanli Lingji. "Scaling embodied foundation models must move beyond manual data collection toward industrial scenarios, and Atomix's massive real-world data is precisely the fuel that gets the flywheel spinning. By closing this loop, Yuanli Lingji has secured first-mover access to scaled embodied intelligence deployment. Our next goal is to build the world's leading general-purpose embodied foundation model."

02/

Chuhang Technology Closes Series C Funding

Recently, Qiming Venture Partners portfolio company Chuhang Technology announced the completion of its Series C round, raising over RMB 100 million. The proceeds will primarily fund technology iteration and capacity expansion, continuing to extend the company's leading position in spatial intelligent perception.

As a professional-grade millimeter-wave radar perception solution provider, Chuhang Technology has always treated R&D capability as its foundation. Since its founding in 2018, the company has focused on automotive applications with ADAS intelligent driving at its core, building a scaled product portfolio spanning forward-looking radar, corner radar, vital signs radar, and 4D high-precision radar. Leveraging its underlying "platform-based development + system-level fusion" core technology, it has established a fully autonomous and controllable perception technology moat through end-to-end capabilities.

In the domestic market, Chuhang Technology has entered the supply chains of nearly 30 OEMs including Leapmotor, Geely, Chery Automobile, Great Wall Motor, BAIC Group, and Dongfeng, securing designated projects for nearly 90 mainstream models with over 20 models already in mass production. Its products and technology have obtained ASPICE CL2 international certification, ISO 26262 functional safety certification, and EU CE RED notified body certificates, meeting world-class standards in quality control, software development management, and functional safety, with over 130 authoritative certifications in total. In overseas markets, Chuhang Technology has secured 50 market access certifications, with operations spanning Germany, India, South Korea, Vietnam, Malaysia, and other countries.

Major Partnerships

01/

WeRide and Uber Launch Spain's First Robotaxi Service

Recently, Qiming Venture Partners portfolio company and global autonomous driving technology leader WeRide (NASDAQ: WRD, 0800.HK) and international mobility giant Uber (NYSE: UBER) announced plans to launch Spain's first commercial Robotaxi pilot service in Madrid. This marks WeRide and Uber's first joint foray into the European market, with Madrid becoming the twelfth city globally where WeRide Robotaxis operate.

With support from the Comunidad de Madrid, the commercial Robotaxi service will officially launch within the year. Local users will be able to hail a WeRide Robotaxi through the Uber app with one tap. During the initial operation phase, vehicles will be equipped with professionally trained safety operators; going forward, as key operational metrics are progressively achieved, WeRide, AVOMO, and Uber have committed to deploying hundreds more Robotaxis and advancing pure unmanned Robotaxi commercial services across Madrid's core urban areas.

Dr. Tony Han, founder and CEO of WeRide, stated: "Deploying Robotaxis in a rapidly developing city like Madrid fully demonstrates WeRide's safe operations capabilities in real-world complex road scenarios. Spain is the fifth European market WeRide has entered, further solidifying our leading position as a trusted Robotaxi operator in Europe. Together with Uber, we are deeply integrating WeRide's autonomous driving technology with Uber's global mobility platform to jointly accelerate large-scale commercialization of Robotaxis."

Technology Strength

01/

Hyperstrong Signs Over 1GWh of Orders in the Balkans

Recently, Qiming Venture Partners portfolio company Hyperstrong (688411.SH) signed over 1GWh of orders in the Balkan region, including large-scale energy storage projects totaling more than 900MWh in Romania; Croatia and Serbia simultaneously added new large-scale storage and C&I storage orders totaling 75MWh, covering multiple application scenarios in Southeast Europe and continuing to deepen the company's strategic European footprint.

As an emerging hotspot for Europe's energy transition, the Balkan region continues to expand renewable energy installations, with increasingly urgent needs for grid regulation and renewable energy integration. This concentrated landing of over 1GWh of orders represents a critical move in Hyperstrong's globalization strategy of "deeply cultivating Western and Central Europe while radiating into Southeast Europe," further solidifying the company's core competitiveness and growth momentum in the European energy storage market.

R&D Progress

01/

Tigermed Presents at 2026 ASCO Annual Meeting

Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting — the most influential annual gathering in global oncology — was held at McCormick Place Convention Center in Chicago. Qiming Venture Partners portfolio company Tigermed (300347.SZ, 03347.HK) brought clinical experts and management from the United States, China, Europe, Asia-Pacific, and Australia to the event, systematically presenting its globalized one-stop R&D services and solutions spanning the full process from drug discovery and clinical trials to regulatory submissions.

During the conference, the Tigermed booth attracted numerous partners from pharmaceutical companies and research institutions. The Tigermed team shared extensive clinical development experience with global partners, covering key aspects from strategic planning to clinical execution in oncology projects. The team also engaged in wide-ranging discussions on enhancing clinical research quality and execution efficiency around cross-border development strategies, multi-regional collaboration, and project implementation in practical scenarios.

02/

Zai Lab Partner's Povetacicept BLA for IgA Nephropathy Accepted by FDA

Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ:ZLAB, 09688.HK) partner Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for povetacicept for the treatment of adult immunoglobulin A nephropathy (IgAN). Povetacicept is an investigational engineered fusion protein and a dual inhibitor of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept would become the first commercial therapy in Vertex's emerging nephrology pipeline.

As disclosed in March, this submission was supported by positive interim analysis data at week 36 from the ongoing Phase 3 RAINIER study of povetacicept in IgAN. Results showed a statistically significant and clinically meaningful reduction in proteinuria (a key marker of kidney disease progression) compared to placebo. RAINIER achieved its primary goal: patients treated with povetacicept demonstrated a 52.0% reduction in urine protein-to-creatinine ratio (UPCR) from baseline at week 36, representing a 49.8% reduction versus placebo that was statistically significant and clinically meaningful (P<0.0001). The reduction in proteinuria was consistent across all prespecified subgroups.

03/

RayBio's Respacio® Absorbable Spacer Hydrogel Successfully Applied in Prostate Cancer SBRT

Recently, Qiming Venture Partners portfolio company RayBio achieved a new clinical milestone with its self-developed Respacio® tumor radiotherapy "absorbable spacer hydrogel" following its market approval — successfully completing the nation's first application in prostate cancer stereotactic body radiation therapy (SBRT) at Chongqing University Cancer Hospital (Chongqing Cancer Hospital). This represents not only an important expansion beyond Respacio®'s cervical cancer indication, but also marks it as the first spacer hydrogel product successfully applied in advanced radiotherapy techniques such as SBRT, setting a new technical benchmark for precision radiotherapy in China.

In this first national application at Chongqing University Cancer Hospital, the clinical team used a minimally invasive approach to precisely inject Respacio® hydrogel into the space between the prostate and rectum prior to SBRT treatment. Upon injection, the product rapidly solidified in situ, forming a stable physical barrier that displaced the rectum posteriorly, significantly increasing the spatial distance between the tumor and rectum. This enabled the high-dose radiation zone to more concentratedly target the prostate while substantially reducing radiation dose to the rectum, fundamentally mitigating the risk of radiation-induced rectal injury. The hydrogel fully degrades within months post-procedure, eliminating the need for secondary surgical removal.

04/

OriCell's GPC3 CAR-T Approved by NMPA for Phase II Confirmatory Trial in Late-Line Advanced Hepatocellular Carcinoma

Qiming Venture Partners portfolio company and global innovative tumor immunotherapy leader OriCell recently announced that its self-developed GPC3-targeted chimeric antigen receptor autologous T-cell injection (code name: Ori-C101) has received approval from China's National Medical Products Administration (NMPA) to enter a Phase II confirmatory clinical trial for GPC3-positive late-line advanced hepatocellular carcinoma (HCC). This study is a prospective, randomized controlled, open-label, multi-center registration clinical trial designed to evaluate the efficacy and safety of Ori-C101 in patients with advanced hepatocellular carcinoma who have failed after two or more lines of prior treatment.

According to publicly available information, this is the world's first GPC3-targeted immune cell therapy to enter a confirmatory clinical trial, and the first CAR-T therapy for liver cancer to advance to a Phase II confirmatory randomized controlled study, marking an important leap for China in solid tumor cell therapy from "following" to "leading." It also means Ori-C101 has the potential to become the world's first CAR-T drug for liver cancer treatment.

Dr. Yang Huanfeng, co-founder, chairman and CEO of OriCell, stated: "The approval of Ori-C101 to enter Phase II confirmatory clinical trials not only strongly validates the scientific rigor and feasibility of our technology platform, but also signals that OriCell has entered a new phase of growth. With the regulatory pathway now clear, we will fully advance Ori-C101's confirmatory clinical development, striving to bring new breakthrough treatment options to patients as soon as possible. We believe these developments will also provide solid support for Chinese innovative drugs to execute 'going global' strategies and compete in global markets."

Product Launches

01/

Noitom Robotics Officially Launches ModalityNet

Recently, Qiming Venture Partners portfolio company Noitom Robotics officially launched the ModalityNet.com data platform. The platform focuses on human-centric omni-modal data, introducing three core datasets — HiPHI-MOV, HiPHI-OM, and ITW — providing data infrastructure for the next generation of embodied intelligence to robotics companies, embodied intelligence model R&D teams, and academic researchers.

"What the industry needs is not just data, but reliable data infrastructure — validated end-to-end processes for collection, calibration, quality assurance (QA), and cross-embodiment mapping, plus a true data system that serves model training and robot learning," said Dr. Dai Ruoli, founder & CEO of Noitom Robotics. "Our goal with ModalityNet is to make data about 'humans interacting with the world' scalable, evaluable, and reusable, thereby advancing the entire embodied intelligence ecosystem."

02/

Yunji Technology and Qi'anxin Jointly Launch "High-Security Robot"

Recently, the 2026 Global Digital Economy Conference Digital Security Forum & Beijing Cybersecurity Conference (BCS2026) was held at Beijing National Convention Center. Qiming Venture Partners portfolio company Yunji Technology (02670.HK) co-founder & CEO Li Quanyin was invited to attend, and on-site jointly launched the "Yunji High-Security Robot" with Qi'anxin Group, targeting high-security-grade business scenarios in state-owned enterprises, government, power, and manufacturing with a four-layer security solution covering trusted identity, traceable behavior, data leak prevention, and compliance control.

This launch represents the comprehensive product-side implementation of this security system. From single products to system security, from enterprise practice to ecosystem co-building — Yunji Technology is using security as its foundation to propel the embodied intelligence industry into a new phase of "high-security trustworthiness." "Future robots must not only move, interact, and execute tasks, but also have trusted identities, clear boundaries, risk perception, and continuous protection," Li Quanyin stated. When robots become the core node connecting digital and physical worlds, security is no longer one company's moat, but the foundation for the entire industry's scaled development.

---

Past Issues

Qiming Perspectives | Duane Kuang of Qiming Venture Partners: Embrace the Cycle, Ride Through the Cycle — AI Will Be an Ultra-Long Technology Cycle Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.18, 2026.6.2 Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including ChinaVenture's 2025 China Best Venture Capital Firm TOP4

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare innovation.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, with more than 210 exiting through listings on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or through M&A and other means. Over 80 companies have become recognized unicorns or super-unicorns.

Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), Hyperstrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Abogen, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.